Inflammation-pathway mRNAs implicated in age-related macular degeneration

Inflammation-pathway mRNAs implicated in age-related macular degeneration (AMD) represent a broad collection of messenger RNA transcripts that encode proteins driving chronic inflammation and tissue damage in the aging retina. This group includes mRNAs for the alternative complement pathway (e.g., CFH, C3, C5), pro-inflammatory cytokines (e.g., IL-6, TNF-α), and components of the NLRP3 inflammasome (Source: NIH National Eye Institute; PubMed PMID: 26059355). In AMD, the dysregulation of these transcripts leads to an overactive innate immune response, resulting in the senescence of retinal pigment epithelium (RPE) cells and the subsequent loss of photoreceptors. While these mRNAs are not typically considered a single molecular target, they serve as the genetic templates for proteins currently targeted by FDA-approved therapies like pegcetacoplan and avacincaptad pegol (Source: Nature Medicine, doi:10.1038/nm.2798). Emerging research into RNA-based therapeutics, such as siRNA and antisense oligonucleotides, seeks to modulate these pathways at the pre-translational level to achieve more durable clinical outcomes (Source: Journal of Clinical Medicine, PMID: 33466751). Understanding the expression patterns of these mRNAs is crucial for identifying transcriptomic biomarkers that can predict disease progression and patient response to anti-inflammatory treatments.

Other names

AMD inflammatory transcriptomeRetinal inflammatory gene expression profileComplement and cytokine mRNA signatures in AMDInflammatory pathway transcripts in retinal degeneration

Current therapeutic strategies primarily target the protein products encoded by these mRNAs, such as complement factors C3 and C5, to inhibit the inflammatory cascade and prevent retinal pigment epithelium (RPE) damage. Experimental approaches like RNA interference (RNAi) or antisense oligonucleotides (ASOs) aim to directly degrade or inhibit the translation of these mRNAs to provide sustained suppression of inflammatory signaling.